Enlivex Ltd. Sample Contracts
Bioblast Pharma Ltd. _________ Class A Units Consisting of One Ordinary Share and One Series A Warrant to Purchase 0.75 of an Ordinary Share __________ Class B Units Consisting of One Pre-Funded Series B Warrant to Purchase One Ordinary Share and One...Underwriting Agreement • April 5th, 2017 • Bioblast Pharma Ltd. • Pharmaceutical preparations • New York
Bioblast Pharma Ltd., a corporation incorporated under the laws of the State of Israel (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Bioblast Pharma Ltd., the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named in Schedule 1 to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), an aggregate of (a) ________ Class A Units (the “Firm Class A Units”), with each Firm Class A Unit consisting of (i) one Company ordinary share (each a “Firm Share”), par value NIS 0.01 per share (the “Ordinary Shares”) and (ii) one Series A Warrant (each a “Series A Warrant”), each warrant to purchase [0.75] of an Ordinary Share at an exercise price of $[___]1 per share and (b) _______ Class B Units (the “Firm Class B Units”)
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 18th, 2016 • Bio Blast Pharma Ltd. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 16, 2016, between BioBlast Pharma Ltd., an Israeli corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
Shares Bio Blast Pharma Ltd. Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • July 15th, 2014 • Bio Blast Pharma Ltd. • Pharmaceutical preparations • New York
Bio Blast Pharma Ltd., a corporation incorporated under the laws of the State of Israel (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Bio Blast Pharma Ltd., the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule 1 to this Agreement (the “Underwriters”), for whom you are acting as Representatives (the “Representatives”), an aggregate of ________ shares (the “Firm Shares”) of the Company’s ordinary shares, par value NIS 0.01 per share (the “Ordinary Shares”). The respective amounts of the Firm Shares to be purchased by each of the several Underwriters are set forth opposite their names on Schedule 1 hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional ___________ Ordinary Shares (t
AT THE MARKET OFFERING AGREEMENTAt the Market Offering Agreement • October 22nd, 2020 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations • New York
Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows:
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 29th, 2024 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of May 27, 2024, between Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 5th, 2020 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 1, 2020, between Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
ORDINARY SHARE PURCHASE WARRANT Enlivex Therapeutics Ltd.Ordinary Share Purchase Warrant • March 5th, 2020 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations
THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”), and on or prior to 5:00 p.m. (New York City time) on March 4, 2022 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), up to ______ of the Company’s Ordinary Shares (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SERIES B PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT Enlivex Therapeutics Ltd.Warrant Agreement • May 29th, 2024 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations
THIS SERIES B PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”), and on or prior to 5:00 p.m. (New York City time) on the earlier of (i) May 27, 2029 and (ii) the 60th day following the date on which the Company publicly announces the occurrence of the Series B Milestone Event (the earlier of such dates, the “Termination Date”), but not thereafter, to subscribe for and purchase from Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), up to ______ of the Company’s ordinary shares, NIS 0.40 per share (“Ordinary Shares”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Ordinary Share under this Warrant shall be equal to th
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT Enlivex Therapeutics Ltd.Pre-Funded Ordinary Share Purchase Warrant • May 29th, 2024 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations
THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”), and until this Warrant is exercised in full (the “Termination Date”) to subscribe for and purchase from Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), up to ______ of the Company’s ordinary shares, NIS 0.40 per share (“Ordinary Shares”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT Enlivex Therapeutics Ltd.Placement Agent Ordinary Share Purchase Warrant • March 5th, 2020 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations
THIS PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”), and on or prior to 5:00 p.m. (New York City time) on March 4, 2022 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), up to ______ of the Company’s Ordinary Shares (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain engagement letter, dated as of March 1, 2020, by and between the Company and H.C. Wainwright & Co., LLC.
CO-PLACEMENT AGENCY AGREEMENTCo-Placement Agency Agreement • March 18th, 2016 • Bio Blast Pharma Ltd. • Pharmaceutical preparations • New York
ORDINARY SHARE PURCHASE WARRANT bio blast pharma ltd.Ordinary Share Purchase Agreement • March 18th, 2016 • Bio Blast Pharma Ltd. • Pharmaceutical preparations
THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after September ___, 2016 (the “Initial Exercise Date”) and on or prior to the close of business on September ___, 2021 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Bio Blast Pharma Ltd., an Israeli corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Ordinary Shares, NIS 0.01 par value (the “Ordinary Share(s)”). The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Indemnification AgreementIndemnification Agreement • April 8th, 2014 • Bio Blast Pharma Ltd. • Pharmaceutical preparations
This Indemnification Agreement (this "Agreement") is made as of ___________, 2014, by and between Bioblast Pharma Ltd., a company organized and existing under the laws of Israel (the "Company") and ____________ I.D. No / Passport No ____________ ("Indemnitee").
Enlivex Therapeutics Ltd. Ordinary Shares (par value NIS0.40 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • December 30th, 2022 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations • New York
Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. and JMP Securities LLC (collectively, the “Agents”), as follows:
ENLIVEX THERAPEUTICS LTD. AMENDED & RESTATED UNDERWRITING AGREEMENTUnderwriting Agreement • February 12th, 2021 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations • New York
SECURITIES PURCHASE AGREEMENT AMONG BIOBLAST pharma ltd. and THE INVESTORS PARTY HERETOSecurities Purchase Agreement • March 27th, 2019 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of March 11, 2019, is by and among BioBlast Pharma Ltd., a company formed under the laws of the State of Israel (the “Company”), and each investor identified on the signature pages hereto (each, an “Investor” and collectively, the “Investors”).
AGREEMENTLease Agreement • April 30th, 2024 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations
This Agreement ( “Agreement”), made effective as of 31th of Marc, 2024 (“Effective Date”), is entered into by and between BioHarvest Ltd., an Israeli company, having an address at 3th Pekeris St. Rehovot (“BioHarvest”), and Enlivex Therapeutics R&D, Ltd., an Israeli company having an address at EINSTEIN 14TH St, NESS ZIONA (“Enlivex”).
AMENDED AND RESTATED SERVICES AGREEMENTServices Agreement • July 15th, 2014 • Bio Blast Pharma Ltd. • Pharmaceutical preparations • Tel-Aviv
THIS AMENDED AND RESTATED SERVICES AGREEMENT (this “Agreement”) is entered into on April 22, 2014 by and between Bio Blast Pharma Ltd. ("Company") and Dalia Megiddo through DM Medica Ltd. (“Service Provider").
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • February 19th, 2019 • Bioblast Pharma Ltd. • Pharmaceutical preparations • New York
THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is made as of February 15, 2019, by and among Seelos Therapeutics, Inc., a Nevada corporation (“Buyer”), and Bioblast Pharma, Ltd., an Israeli corporation (“Seller”). Buyer and Seller may be referred to herein collectively as the “Parties” and individually as a “Party.”
INDEMNIFICATION AGREEMENTIndemnification Agreement • April 30th, 2019 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations
This Indemnification Agreement (“Indemnification Agreement”) is being entered into by and between ___________ (the “Indemnitee”) and Enlivex Therapeutics Ltd., a company organized under the laws of the state of Israel (the “Company”), effective as of ___________, pursuant to the resolutions of the Board of Directors of the Company (the “Board”), dated ___________, as approved by the Company’s shareholders on ___________.
THIRD AMENDMENT TO CONSULTING AGREEMENTConsulting Agreement • April 30th, 2025 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations
THIS THIRD AMENDMENT (the “Third Amendment”) is entered into as of November 7, 2024, by and between Enlivex Therapeutics, Ltd., a company organized under the laws of the State of Israel, corporate number 51373620, whose address is at 14 Einstein Street, Ness Ziona, Israel 7403618 (the “Company”) and A.S. Novik Ltd., a company organized under the laws of the State of Israel, corporate number 513439273, whose address is 30 Anni Maamin Street, Ramat Hasharon, Israel 4721249 (the “Consultant”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 28th, 2026 • Enlivex Ltd. • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of [__], 2026, between Enlivex Ltd., a company organized under the laws of the State of Israel (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • November 19th, 2018 • Bioblast Pharma Ltd. • Pharmaceutical preparations • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of November 19, 2018 (this “Agreement”), is entered into by and among Bioblast Pharma Ltd., an Israeli company (the “Company,” or “Bioblast”), Enlivex Therapeutics Ltd., an Israeli company (“Enlivex”), Dr. Dalia Megiddo, as the Holders’ Representative (as defined herein), Computershare Inc., a Delaware corporation, as Rights Agent (the “Rights Agent”) and as initial CVR Registrar (as defined herein) and Altshuler Shaham Trusts Ltd. (“Altshuler” or the “Successor Holders’ Representative”).
CONSULTING AGREEMENTConsulting Agreement • April 30th, 2019 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations
Hadasit Medical Research Services and Development Ltd. (“Hadasit”), whose address, for the purposes hereof, is P.O.Box 12000, Jerusalem 91120;
ORDINARY SHARE PRE-FUNDED PURCHASE WARRANT Enlivex Therapeutics Ltd.Ordinary Share Pre-Funded Purchase Warrant • November 24th, 2025 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations
THIS ORDINARY SHARE PRE-FUNDED PURCHASE WARRANT (the “Warrant”) certifies that, for value received, __________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”), to subscribe for and purchase from Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), up to __________________ of the Company’s ordinary shares, NIS 0.40, per share (“Ordinary Shares”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
INDEMNIFICATION AGREEMENTIndemnification Agreement • March 25th, 2026 • Enlivex Ltd. • Pharmaceutical preparations
This Indemnification Agreement (“Indemnification Agreement”) is being entered into by and between ___________ (the “Indemnitee”) and Enlivex Therapeutics Ltd., a company organized under the laws of the state of Israel (the “Company”), effective as of ___________, pursuant to the resolutions of the Board of Directors of the Company (the “Board”), dated ___________, as approved by the Company’s shareholders on ___________.
JOINDER AND FIRST AMENDMENT TO ASSET MANAGEMENT AGREEMENTAsset Management Agreement • March 24th, 2026 • Enlivex Ltd. • Pharmaceutical preparations
This JOINDER AND FIRST AMENDMENT TO ASSET MANAGEMENT AGREEMENT, dated as of March 23, 2026 (this “Amendment”), is made by and among Enlivex Ltd., a company organized under the laws of the State of Israel (formerly Enlivex Therapeutics Ltd., the “Company” or the “Client”), Elinnovation Labs Ltd., a company organized under the laws of the State of Israel (the “Asset Manager”), and Lind Global Asset Management XIV LLC, a Delaware limited liability company (the “Investor”).
ASSET MANAGEMENT AGREEMENTAsset Management Agreement • November 24th, 2025 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations
This ASSET MANAGEMENT AGREEMENT (this “Agreement”), effective November 20, 2025 (the “Effective Date”) is made and entered into, by and between:
AMENDMENT NO. 1 TO SENIOR SECURED CONVERTIBLE PROMISSORY NOTESenior Secured Convertible Promissory Note • August 11th, 2026 • Enlivex Ltd. • Pharmaceutical preparations • New York
This Amendment No. 1 to Senior Secured Convertible Promissory Note (this “Amendment”) is entered into as of August 11, 2026 (the “Amendment Date”), by and between Lind Global Asset Management XIV LLC, a Delaware limited liability company (the “Holder”), and Enlivex Ltd., a company organized under the laws of the State of Israel (the “Maker” or the “Company”).
AGREEMENT AND PLAN OF MERGER By and Among BIOBLAST PHARMA LTD. TREBLAST LTD. AND ENLIVEX THERAPEUTICS LTD. Dated as of November 19, 2018Merger Agreement • November 19th, 2018 • Bioblast Pharma Ltd. • Pharmaceutical preparations
This AGREEMENT AND PLAN OF MERGER, dated as of November 19, 2018 (this “Agreement”), is by and among BIOBLAST PHARMA LTD., a company formed under the laws of the State of Israel (“Bioblast”), TREBLAST LTD., a company formed under the laws of the State of Israel and wholly owned by Bioblast (“Merger Sub”), and ENLIVEX THERAPEUTICS LTD., a company formed under the laws of the State of Israel (“Enlivex”).
RESEARCH AGREEMENTResearch Agreement • April 30th, 2020 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations
This Research Agreement (“Agreement”) is made and entered in Jerusalem as of May 12, 2019 (the “Effectivev Date”), by and between Enlivex Therapeutics Ltd., a company duly incorporated under the laws of the State of Israel having its registered office at 14 Einstein St. Ness-Ziona, Israel (the “Company”) AND:
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 24th, 2025 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of [●], 2025, between Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 28th, 2026 • Enlivex Ltd. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of July 28, 2026, between Enlivex Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
ORDINARY SHARE PURCHASE WARRANT Enlivex Therapeutics Ltd.Ordinary Share Purchase Warrant • November 24th, 2025 • Enlivex Therapeutics Ltd. • Pharmaceutical preparations
THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”), and on or prior to 5:00 p.m. (New York City time) on November [●], 2030 (the “Termination Date”), but not thereafter, to subscribe for and purchase from Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), up to ______ of the Company’s ordinary shares, NIS 0.40 per share (“Ordinary Shares”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued in connection with the transactions contemplated by the Purchase Agreement (as defined below).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 24th, 2026 • Enlivex Ltd. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (as amended, supplemented, restated and/or modified from time to time, this “Agreement”) is entered into as of March 23, 2026, by and between Enlivex Ltd., a company organized under the laws of the State of Israel (the “Company”), and Lind Global Asset Management XIV LLC, a Delaware limited liability company (the “Investor”).